Biotech »

Revive Therapeutics Announces Initiation of Research Discovery Program of Cannabinoid-Based Therapies Targeting Liver Diseases

Revive Therapeutics Announces Initiation of Research Discovery Program of Cannabinoid-Based Therapies Targeting Liver Diseases

Alpha Stox March 1, 2017 Comments Off

TORONTO, ONTARIO–(Marketwired – March 1, 2017) - Revive Therapeutics Ltd. (“Revive” or the “Company”) (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical

Read More »
RepliCel closes $3.16-million in private placements

RepliCel closes $3.16-million in private placements

Alpha Stox February 24, 2017 Comments Off

Mr. Lee Buckler reports REPLICEL LIFE SCIENCES ANNOUNCES CLOSING OF BROKERED AND NON-BROKERED PRIVATE PLACEMENT RepliCel Life Sciences Inc. has completed its financing announced on Feb. 7, 2017, which consisted of a brokered private

Read More »
Revive Therapeutics Announces Expansion into Cannabinoid-Based Therapies Targeting Liver Diseases

Revive Therapeutics Announces Expansion into Cannabinoid-Based Therapies Targeting Liver Diseases

Alpha Stox February 16, 2017 Comments Off

TORONTO, ONTARIO–(Marketwired – Feb. 16, 2017) - Revive Therapeutics Ltd. (“Revive” or the “Company”) (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical

Read More »
3D appoints Glorikian to business advisory board

3D appoints Glorikian to business advisory board

Alpha Stox February 15, 2017 Comments Off

Mr. Jason Flowerday reports 3D SIGNATURES INC. ADDS MEDICAL DIAGNOSTIC EXPERT TO BUSINESS ADVISORY BOARD Harry Glorikian has joined 3D Signatures Inc.’s business advisory board. Mr. Glorikian has over 30 years of private and

Read More »
Revive starts phase II cystinuria clincal study

Revive starts phase II cystinuria clincal study

Alpha Stox February 7, 2017 Comments Off

Mr. Craig Leon reports REVIVE THERAPEUTICS ANNOUNCES INITIATION OF A PHASE 2 STUDY OF REV-004 (BUCILLAMINE) IN CYSTINURIA Revive Therapeutics Ltd. has initiated a phase II clinical study in patients with cystinuria in the

Read More »
3D Signatures provides details on Kilmer Lucas hire

3D Signatures provides details on Kilmer Lucas hire

Alpha Stox January 16, 2017 Comments Off

Mr. Stephen Kilmer reports 3D SIGNATURES INC. PROVIDES FURTHER DETAIL ON KILMER LUCAS ENGAGEMENT In addition to its press release on Dec. 22, 2016, 3D Signatures Inc. has provided further details regarding its engagement

Read More »
New Study Shows 3D Signatures’ Telomere Analysis May Be an Effective Biomarker for Monitoring High Risk Prostate Cancer Patients

New Study Shows 3D Signatures’ Telomere Analysis May Be an Effective Biomarker for Monitoring High Risk Prostate Cancer Patients

Alpha Stox January 9, 2017 Comments Off

WINNIPEG, MB–(Marketwired – January 09, 2017) - Data from a new study1 published recently in Urologic Oncology involving men with localized high-risk prostate cancer suggests that the use of 3D Signatures Inc.’s (TSX VENTURE: DXD) (OTCQB: TDSGF) (FRANKFURT: 3D0) (the “Company”

Read More »
Veritas Pharma arranges $2-million private placement

Veritas Pharma arranges $2-million private placement

Alpha Stox January 9, 2017 Comments Off

Dr. Lui Franciosi reports VERITAS ANNOUNCES PRIVATE PLACEMENT Veritas Pharma Inc. has arranged a non-brokered private placement offering of up to 9,090,910 units at a price of 22 cents per unit for aggregate gross

Read More »
RepliCel Life Sciences’ CEO is pumped up for 2017

RepliCel Life Sciences’ CEO is pumped up for 2017

Alpha Stox January 5, 2017 Comments Off

Mr. Lee Buckler reports REPLICEL CEO PROVIDES 2017 FORECAST RepliCel Life Sciences Inc. is providing an update to shareholders from its president and chief executive officer, R. Lee Buckler. Dear Shareholders, In my communication

Read More »
Concordia signs Donnatal co-promotion deal with RedHill

Concordia signs Donnatal co-promotion deal with RedHill

Alpha Stox January 3, 2017 Comments Off

Mr. Allan Oberman reports CONCORDIA INTERNATIONAL CORP. ANNOUNCES CO-PROMOTE AGREEMENT FOR DONNATAL Concordia International Corp., together with its subsidiaries, has entered into a three-year, co-promotion agreement with RedHill Biopharma Ltd. through which the companies

Read More »
Newsletterpopup_top_1

Your Name (required)

Your Email (required)

captcha

Newsletterpopup_bottom_1